We are launching the five new products in the new manufacturing facility and they're all pharmaceuticals and this should lead to an increase in pharma numbers.
The capital expansion program commenced in June 2022 and is expected to complete in 2024
The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke
Dr. Pedrocchi is currently an Independent Strategic Advisor and Non-Executive Director to private and public healthcare companies.
India is at the forefront of research in cardiology worldwide but making indigenous products is what we are lacking & it needs to be improved
The Centre aims at promoting innovation among the scientific community to improve healthcare solutions around the globe
Indonesia national agency for drug and food control, BPOM, approved QDENGA for use in individuals 6 to 45 years of age
Desvenlafaxine Extended-Release Tablets, 25 mg is a generic equivalent of Pristiq Extended-Release Tablets, 25 mg of PF PRISM C.V.
The approved product has an estimated market size of around US $62 million for the twelve months ending June 2022 according to IQVIA
This rapid analytical technique provides additional information about the polymorph and solid-state properties of active pharmaceutical ingredients (APIs)
Subscribe To Our Newsletter & Stay Updated
